Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 18 tulemused
Bioimaging Study of 89Zr-M7824 in NSCLC
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Immune checkpoint inhibitors have shown improved treatment outcome in patients with NSCLC; however, there is room to further improve benefits. A novel agent such as M7824, a fusion protein which targets the tumor microenvironment where it blocks both the cell intrinsic PD-L1/PD-1 interaction and the
89Zr-atezolizumab PET Scan and Lobular Breast Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Patients with a high risk diffuse large B-cell lymphoma (DLBLC) with an international prognostic score (IPI) > 2, have a high risk of relapse even after achieving a metabolic complete remission with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) chemo-immunotherapy.
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Participants receive standard of care 18F-FDG-PET/CT and/or 18F-FDG-PET/MRI to assess their cancer for surgical excision. Participants than receive panitumumab-IRDye800 dye and 89Zr-panitumumab, both by intravenous (IV) infusion, on Day 0. Participants will undergo 89Zr-panitumumab PET/CT imaging on
PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The programmed death 1 (PD1)/ programmed death ligand 1 (PD-L1) pathway plays an important role in regulating the T-cell anti tumor response. Blocking this interaction with the anti PD-L1 monoclonal antibody avelumab is effective in patients with non-small cell lung cancer (NSCLC) resulting in
A Trial of KB004 in Patients With Glioblastoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
89Zr-AMG211 PET Imaging Study
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
MPDL3280A-imaging-IST-UMCG
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The Programmed cell death protein 1 (PD1)/Programmed death-ligand 1 (PD-L1) axis is an important immune checkpoint for T cell activation that is used by tumors to evade the host immune response. Blocking signaling with the PD-L1 antibody MPDL3280A results in ongoing T cell activity and can induce
Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Patient selection for hormone therapy and anti-HER2 therapy is based on the presence of their respective targets, the ER and HER2, as currently assessed on tumor tissue by molecular biological techniques. In primary breast cancer, both ER and HER2 are powerful predictors for response to ER or HER2
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated.
- A medical history, which
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Multiple Myeloma (MM) is a clonal B cell disorder characterised by a monoclonal plasma cell population in bone marrow, with bone pain, anaemia, hypercalcaemia, and kidney dysfunction as clinically presenting symptoms. Osseous involvement is one of the most predominant features of patients with MM;
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The main objective of the trial is to prospectively evaluate the ability of a zirconium 89 labelled trastuzumab PET, to predict, before initiation of the treatment, treatment failure to a new targeted drug: T-DM1.
At the same time, the early FDG-PET/CT, performed after 1 course of T-DM1, will also
Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
